Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.79 |
| ▸ | EGFR | P00533 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 4/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CRHBP | P24387 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334818 | 0.91 | EGFR (0.77) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL3244626 | 0.88 | ALK (0.77) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL1192454 | 0.88 | EGFR (1.00) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL30552991 | 0.88 | EGFR (1.00) | ALKEGFRABCG2 | |
| SCHEMBL3244621 | 0.88 | EGFR (1.00) | ALKEGFRABCG2 | |
| SCHEMBL6663823 | 0.86 | ALK (0.74) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL5532975 | 0.85 | ALK (0.76) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL17124151 | 0.84 | EGFR (0.84) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL1387227 | 0.83 | EGFR (0.80) | ALKEGFRALDH1A1MAPTHTT | |
| SCHEMBL29199908 | 0.83 | ALK (0.70) | ALKEGFRALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | ALK 24/4885EGFR 1/4885ALDH1A1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.